Navigation Links
ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress
Date:6/4/2009

m. CEST in the Bella Center.

About ACTEMRA(R) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody being studied for the treatment of RA. Studies demonstrate that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. The extensive clinical development program conducted by Roche includes five Phase III clinical studies and has enrolled more than 4,000 patients in 41 countries, including the United States. The five Phase III studies are completed and have reported meeting their primary endpoints. ACTEMRA is currently under review by the FDA in the United States.

ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan. ACTEMRA (known as RoACTEMRA in Europe), was also recently approved in the European Union, Switzerland and India.

The serious adverse events reported in ACTEMRA clinical studies include serious infections, gastrointestinal perforations and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, hypertension and increased ALT. Increases in liver enzymes (ALT and AST) were seen in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical out
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis
2. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting
5. Studies Reveal Exposure to Pesticides During Pregnancy Increases Risk of Premature Birth, Low-Birth Weight, Neurological Problems and Diabetes
6. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
7. 2 studies examine medical consequences of police use of force during restraint
8. Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
9. Studies show LAM patients participate in clinical trials to help others, not themselves
10. Traumatic brain injury haunts children for years with variety of functional problems: Two studies
11. Review finds conflicts of interest in many cancer studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut ... Trail by stepping off Springer Mountain and heading north. Since that day, Phil has ... Connecticut and was greeted by friends and family. He visited CCAR and left an ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and warm-season ... type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. ... introduction of this new type of sod, Super-Sod is giving away red Adirondack chairs ...
(Date:7/31/2015)... ... ... Ticket Down is a reliable source for authentic tickets for the 2015 ... festival will end on Sunday, August 2nd. , Music fans have traveled ... unique and unbelievably popular festival attracts the best in entertainment from around the world. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy ... comes time to cook the next meal, making July the most appropriate to be ... grilling tips and recipes. , Make the next cookout different than the ones in ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... 12 Repligen Corporation (Nasdaq: RGEN ), ... A products, announced today that the Company has received ... practices for manufacturing and quality systems. ISO certification ... manufacture of products and related services underlying its Protein ...
... and CEO, Scott Grisanti, Publishes Letter Outlining Strategy, ... 12 MedClean Technologies, Inc. (OTC Bulletin Board: ... for the onsite treatment and disposal of regulated ... CEO, Scott Grisanti, has published a letter to ...
... Inc., a premier,technology consulting firm, and Studio Velo, an ... the launch of a new bike club dedicated,to the ... good cause,the American Brain Tumor Association (ABTA). , ... The Studio Velo/Kovarus Cycling Club ...
... Health Integrated, the leading Targeted Population Health ... Analytics company, are partnering to jointly offer health ... targeted population management with advanced business intelligence. Mede,s ... and accurately informed about areas of particular concern ...
... and Ear Infirmary Joins International Observance To Draw Attention To ... In an effort to combat one of ... and the World Glaucoma Patient Organization have set March 12, ... The day will be marked by awareness and educational events ...
... Historic Perspective and Future DirectionsRALEIGH, N.C., Feb. 12 ... leading Clinical Research Organization, will host a prominent panel ... on February 25. Discussions will include case scenarios on ... are applicable to other fields of infectious disease research.The ...
Cached Medicine News:Health News:Repligen Announces ISO 9001:2000 Certification 2Health News:Repligen Announces ISO 9001:2000 Certification 3Health News:MedClean Technologies Inc. CEO Publishes Letter to Shareholders 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 3Health News:MedeFinance and Health Integrated Partner to Give Health Plans Competitive Advantage 2Health News:MedeFinance and Health Integrated Partner to Give Health Plans Competitive Advantage 3Health News:World Glaucoma Day Set For March 12, 2009 2Health News:World Glaucoma Day Set For March 12, 2009 3Health News:World Glaucoma Day Set For March 12, 2009 4Health News:PRA International Speaking Event: Rational Drug Design and Development in Infectious Diseases 2
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... Therapeutics (Nasdaq: NKTR ) today announced positive ... 2 clinical study evaluating single-agent NKTR-102 in women with ... the study with prior Doxil® (pegylated liposomal doxorubicin or ... RECIST 1.0 criteria (response by tumor imaging) or Gynecologic ...
... 4, 2011 Data presented at the 47th American ... potential of circulating tumor cells (CTC) as a biomarker ... the first randomized, double-blind, placebo controlled Phase III trial ... survival.  Biomarkers are of scientific interest as, if validated, ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials 2Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials 3Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: